Bicycle Therapeutics Ltd Total Liabilities
Bicycle Therapeutics Ltd total liabilities. Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) has total liabilities worth $96.32 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bicycle Therapeutics Ltd (BCYC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bicycle Therapeutics Ltd (2016–2025)
Total liabilities of Bicycle Therapeutics Ltd from 2016 to 2025. This chart illustrates how Bicycle Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Bicycle Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Bicycle Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Newcap Holding A/S
CO:NEWCAP
|
Denmark | Dkr2.42 Million |
|
Asia Electronic Material Co Ltd
TWO:4939
|
Taiwan | NT$1.45 Billion |
|
JADESTONE ENERGY LS -001
F:8KW
|
Germany | €1.02 Billion |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
China | CN¥183.42 Million |
|
Globa Terra Acquisition Corporation Class A Ordinary Shares
NASDAQ:GTERA
|
USA | $1.21 Million |
|
Politeknik Metal Sanayi ve
IS:POLTK
|
Turkey | TL30.41 Million |
|
SinoDaan Co Ltd
SHE:300635
|
China | CN¥972.51 Million |
|
RAINBOW RARE EARTHS LTD
F:RR1
|
Germany | €12.88 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Bicycle Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BCYC current and non-current assets.
Liquidity & Leverage Metrics
Bicycle Therapeutics Ltd Total Liabilities Ratios Explained
Bicycle Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bicycle Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bicycle Therapeutics Ltd (2016–2025)
The table below shows the annual total liabilities of Bicycle Therapeutics Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $107.62 Million | -34.30% |
| 2024-12-31 | $163.81 Million | -27.01% |
| 2023-12-31 | $224.41 Million | +60.49% |
| 2022-12-31 | $139.83 Million | +4.71% |
| 2021-12-31 | $133.54 Million | +103.28% |
| 2020-12-31 | $65.69 Million | +286.51% |
| 2019-12-31 | $17.00 Million | -88.78% |
| 2018-12-31 | $151.45 Million | +24.98% |
| 2017-12-31 | $121.19 Million | +3079.87% |
| 2016-12-31 | $3.81 Million | -- |
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more